Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating a conditioning regimen including Yttrium-90 ibritumomab tiuxetan, etoposide, cyclophosphamide, and autologous hematopoietic stem c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Autologous hematopoietic stem cell transplantation (Autologous hematopoietic stem cell transplantation)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Etoposide (Etoposide)
• Yttrium-90 ibritumomab tiuxetan (yttrium-90 ibritumomab tiuxetan)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-06-18